HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.

Aze Suzanne WilsonCeleste PeelQian WangAthanasios Demetri PananosRichard B Kim

Published in: Alimentary pharmacology & therapeutics (2019)

HLADQA1*05 is independently associated with a high risk of infliximab antibody formation in addition to infliximab loss of response and treatment discontinuation. There may be a role for genotype-guided application of combination therapy in IBD.

Keyphrases

combination therapy
ulcerative colitis
emergency department
drug induced